Author(s): Humm JL, Sartor O, Parker C, Bruland OS, Macklis R
The element radium (Ra) was discovered by the Curies in 1898 and within a decade was in broad scientific testing for the management of several forms of cancer. The compound was known to give rise to a series of both high-energy particulate and penetrating γ-emissions. The latter found an important role in early 20th century brachytherapy applications, but the short-range α-particles seemed much less useful. Although highly cytotoxic when released within a few cell diameters of critical cell nuclei, the dense double-strand break damage was poorly repaired, and concerns regarding treatment-related toxicities and secondary malignancies halted clinical development. Moreover, the most common isotope of Ra has an exceptionally long half-life (>1600 years for (226)Ra) that proved daunting when aiming for a systemic cancer therapy. Fortunately, other radium isotopes have more convenient half-lives while still producing cytotoxic α particles. Radium-223 dichloride has a half-life of 11.4 days, and this isotope was identified as an excellent candidate for radionuclide therapy of cancers metastatic to bone. The calcium-mimetic chemical properties of the radium allowed intravenous infusion with rapid uptake to sites of new bone formation. The highly efficient bone localization suggested a potential therapeutic role for osteoblastic bone metastases, and a series of phase 1, 2, and 3 clinical trials was undertaken to explore this possibility. This series of clinical explorations culminated in the ALSYMPCA trial, an international, placebo-controlled, phase 3 study that accrued 921 symptomatic men with bone-metastatic, castrate-resistant prostate cancer. Results of this trial demonstrated a prolongation of overall survival, and regulatory agencies around the world have now approved this product as a treatment for advanced prostate cancer.
Referred From: https://www.ncbi.nlm.nih.gov/pubmed/25832684
Author(s): Ostrom QT, Gittleman H, Farah P, Ondracek A, Chen Y, et al.
Author(s): Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, et al.
Author(s): Fouladi M, Hunt DL, Pollack IF, Dueckers G, Burger PC, et al.
Author(s): Nelson D, Nelson J, Davis D, Chang C, Griffins T, et al.
Author(s): Parvez T
Author(s): Reese TS, Karnovsky MJ
Author(s): Kreuter J
Author(s): Kreuter J.
Author(s): Delpassand ES, Samarghandi A, Zamanian S, Wolin EM, Hamiditabar M, et al.
Author(s): Shore ND
Author(s): Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, et al.
Author(s): Chanda N, Kan P, Watkinson LD, Shukla R, Zambre A, et al.
Author(s): Bhattacharyya S, Bhattacharya R, Curley S, McNiven MA, Mukherjee P
Author(s): Arvizo RR, Miranda OR, Thompson MA, Pabelick CM, Bhattacharya R, et al.
Author(s): Arvizo RR, Miranda OR, Moyano DF, Walden CA, Giri K, et al.
Author(s): Bhattacharyya S, Singh RD, Pagano R, Robertson JD, Bhattacharya R, et al.
Author(s): Kudgus RA, Walden CA, McGovern RM, Reid JM, Robertson JD, et al.
Author(s): Kennel SJ, Chappell LL, Dadachova K, Brechbiel MW, Lankford TK, et al.
Author(s): McLaughlin MF, Robertson D, Pevsner PH, Wall JS, Mirzadeh S, et al.
Author(s): Woodward J, Kennel SJ, Stuckey A, Osborne D, Wall J, et al.
Author(s): McLaughlin MF, Woodward J, Boll RA, Wall JS, Rondinone AJ, et al.
Author(s): Miller DC, Koslow M, Budzilovich GN, Burstein DE
Author(s): Joshi RP, Hu Q
Author(s): Joshi RP, Schoenbach KH
Author(s): Roth CC, Tolstykh GP, Payne JA, Kuipers MA, Thompson GL